MA46188A - Composés indole substitués par pyridyle - Google Patents
Composés indole substitués par pyridyleInfo
- Publication number
- MA46188A MA46188A MA046188A MA46188A MA46188A MA 46188 A MA46188 A MA 46188A MA 046188 A MA046188 A MA 046188A MA 46188 A MA46188 A MA 46188A MA 46188 A MA46188 A MA 46188A
- Authority
- MA
- Morocco
- Prior art keywords
- pyridyl
- compounds substituted
- indole compounds
- indole
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611030860 | 2016-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46188A true MA46188A (fr) | 2019-07-17 |
Family
ID=59895441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046188A MA46188A (fr) | 2016-09-09 | 2017-09-08 | Composés indole substitués par pyridyle |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10660877B2 (fr) |
| EP (1) | EP3510024B1 (fr) |
| JP (1) | JP7028861B2 (fr) |
| KR (1) | KR102519535B1 (fr) |
| CN (1) | CN109923108B (fr) |
| ES (1) | ES2902504T3 (fr) |
| MA (1) | MA46188A (fr) |
| WO (1) | WO2018049089A1 (fr) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| CN109715617B (zh) | 2016-07-30 | 2022-04-19 | 百时美施贵宝公司 | 作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物 |
| ES2902504T3 (es) | 2016-09-09 | 2022-03-28 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con piridilo |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| EP3661926B1 (fr) * | 2017-08-04 | 2022-02-23 | Bristol-Myers Squibb Company | Composés indole substitués utiles en tant qu'inhibiteurs de tlr7/8/9 |
| CN110997670B (zh) * | 2017-08-04 | 2022-11-01 | 百时美施贵宝公司 | [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物 |
| CN111448190B (zh) * | 2017-11-14 | 2023-09-26 | 百时美施贵宝公司 | 取代的吲哚化合物 |
| KR20200091424A (ko) * | 2017-12-01 | 2020-07-30 | 타이완제이 파마슈티컬스 컴퍼니 리미티드 | 벤젠 축합 헤테로환 화합물 및 그 용도 |
| US20200352931A1 (en) | 2017-12-12 | 2020-11-12 | Phenex Discovery Verwaltungs-GmbH | Oxalamides as modulators of indoleamine 2,3-dioxygenase |
| US12030878B2 (en) | 2017-12-15 | 2024-07-09 | Bristol-Myers Squibb Company | Substituted indole ether compounds |
| MX2020006168A (es) | 2017-12-18 | 2020-08-13 | Bristol Myers Squibb Co | Compuestos de 4-azaindol. |
| WO2019126081A1 (fr) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Composés d'indole à substitution amide utiles en tant qu'inhibiteurs de tlr |
| EA202091474A1 (ru) * | 2017-12-19 | 2020-11-18 | Бристол-Маерс Сквибб Компани | Замещенные индольные соединения, применимые в качестве ингибиторов tlr |
| EP3728253B1 (fr) * | 2017-12-19 | 2024-03-27 | Bristol-Myers Squibb Company | Composés de 6-azaindole |
| JP7287967B2 (ja) * | 2017-12-20 | 2023-06-06 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｌｒ阻害剤として有効なアミノインドール化合物 |
| EA202091530A1 (ru) * | 2017-12-20 | 2020-09-14 | Бристол-Маерс Сквибб Компани | Диазаиндольные соединения |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| KR102730859B1 (ko) | 2017-12-20 | 2024-11-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 및 헤테로아릴 치환된 인돌 화합물 |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019155042A1 (fr) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Nouveaux composés et dérivés de sulfone pour le traitement et la prophylaxie d'une infection virale |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2019195181A1 (fr) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019211799A1 (fr) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle |
| US12157746B2 (en) | 2018-06-05 | 2024-12-03 | Hoffmann-La Roche Inc. | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |
| EP3807270B1 (fr) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Nouveaux composés hétéroaryles hétérocyclyles pour le traitement d'une maladie auto-immune |
| US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
| WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
| CN112638908A (zh) | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的苯并噻唑类化合物 |
| WO2020048596A1 (fr) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Nouveaux composés de pyrazolopyridine pour le traitement d'une maladie auto-immune |
| EP3847170B1 (fr) | 2018-09-06 | 2022-06-22 | F. Hoffmann-La Roche AG | Nouveaux composés amidine cyclique pour le traitement d'une maladie auto-immune |
| ES2963696T3 (es) * | 2018-10-24 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos diméricos de indol sustituidos |
| US12172995B2 (en) | 2018-10-24 | 2024-12-24 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
| EP3873608A1 (fr) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
| EP4371987B9 (fr) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Composés de 6-azabenzimidazole substitués utilisés en tant qu'inhibiteurs de hpk1 |
| WO2020178768A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
| WO2020178769A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
| CN113574063B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| KR102904576B1 (ko) | 2019-05-09 | 2025-12-24 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 벤즈이미다졸론 화합물 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| WO2021067326A1 (fr) | 2019-10-01 | 2021-04-08 | Bristol-Myers Squibb Company | Composés hétéroaryle bicycliques substitués |
| CN114829350B (zh) * | 2019-10-04 | 2024-05-28 | 百时美施贵宝公司 | 经取代的咔唑化合物 |
| CN114599652B (zh) | 2019-10-31 | 2024-07-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物 |
| EP4061816A1 (fr) | 2019-11-19 | 2022-09-28 | F. Hoffmann-La Roche AG | Composés d'hydro-1 h-pyrrolo[1,2-a]pyrazine pour le traitement d'une maladie auto-immune |
| EP4061821B1 (fr) | 2019-11-20 | 2025-08-06 | F. Hoffmann-La Roche AG | Composés de spiro(isobenzofurane azétidine) pour le traitement d'une maladie auto-immune |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| KR102987126B1 (ko) | 2020-03-20 | 2026-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| WO2022022489A1 (fr) * | 2020-07-27 | 2022-02-03 | 江苏恒瑞医药股份有限公司 | Dérivé cyclique condensé d'indole, son procédé de préparation et son utilisation en médecine |
| CN114057754B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 含氮桥环类衍生物、其制备方法及其在医药上的应用 |
| CN114057759B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| US12492188B2 (en) | 2020-08-19 | 2025-12-09 | Bristol-Myers Squibb Company | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis |
| WO2022040267A1 (fr) | 2020-08-19 | 2022-02-24 | Bristol-Myers Squibb Company | Dérivés de 1h-pyrrolo[3,2-c]pyridine et de 1h-pyrrolo[2,3-c]pyridine en tant qu'inhibiteurs de tlr9 pour le traitement de la fibrose |
| EP4200297B1 (fr) | 2020-08-19 | 2026-05-13 | Bristol-Myers Squibb Company | Dérivés de imidazo[1,2-a]pyridine et [1,2,4]triazolo[1,5-a]pyridine en tant qu'inhibiteurs tlr9 pour le traitement de fibrose |
| EP4253387A4 (fr) | 2020-11-26 | 2024-05-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Composé tryciclique fusionné, son procédé de préparation et son utilisation en médecine |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359413A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| TW202440078A (zh) | 2021-09-10 | 2024-10-16 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| KR20240148413A (ko) * | 2022-02-18 | 2024-10-11 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr9의 억제제로서 유용한 치환된 비시클릭 헤테로아릴 화합물 |
| CN116947821B (zh) * | 2022-04-20 | 2025-10-17 | 成都肯迪特生物医药科技有限公司 | 一种化合物及其在制备jak激酶抑制剂中的用途 |
| TW202608468A (zh) | 2024-05-13 | 2026-03-01 | 美商基利科學股份有限公司 | 組合療法 |
| WO2025240246A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec de la ribavirine |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec ribavirine |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0104987A3 (en) | 1998-12-18 | 2002-09-30 | Axys Pharmaceuticals Inc South | Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them |
| US7410975B2 (en) | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
| US20060235037A1 (en) | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
| JP2009532501A (ja) * | 2006-04-04 | 2009-09-10 | ミリアド ジェネティクス， インコーポレイテッド | 疾患および障害のための化合物 |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| ATE495743T1 (de) | 2006-12-01 | 2011-02-15 | Galapagos Nv | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| WO2008152471A1 (fr) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Antagoniste des récepteurs de type toll et ses utilisations |
| WO2009030996A1 (fr) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Composés triazole utilisés comme agonistes du récepteur de type toll (tlr) |
| US8354400B2 (en) | 2008-09-26 | 2013-01-15 | Eisai R&D Co., Ltd. | Benzoxazole compounds and methods of use |
| EP2340243B1 (fr) | 2008-10-17 | 2014-10-08 | Boehringer Ingelheim International GmbH | Composés indole à substitution hétéroaryle utilisés comme inhibiteurs de mmp-13 |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| PL2453895T3 (pl) | 2009-07-16 | 2018-10-31 | Mallinckrodt Llc | (+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne |
| WO2012054862A2 (fr) | 2010-10-21 | 2012-04-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions et méthodes pour traiter le prurit et des troubles dermiques associés |
| MX346387B (es) | 2011-01-12 | 2017-03-02 | Ventirx Pharmaceuticals Inc | Benzoazepinas sustituidas como moduladores de receptores tipo toll. |
| DK2663555T3 (en) | 2011-01-12 | 2017-03-27 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
| BR112013030894A2 (pt) | 2011-06-01 | 2016-08-16 | Janus Biotherapeutics Inc | moduladores do sistema imune |
| AU2012262021B2 (en) | 2011-06-01 | 2016-07-28 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| CN103874702B (zh) | 2011-07-15 | 2015-12-09 | 杨森制药公司 | 作为γ分泌酶调节剂的经取代的吲哚衍生物 |
| CA2850932A1 (fr) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Nouveaux modulateurs du systeme immunitaire a base d'imidazole quinoline |
| CA2871589C (fr) | 2012-05-18 | 2020-12-22 | Seiji Hori | Derives d'acide pyridine-2-carboxylique et leurs utilisations comme agonistes de tlr7 |
| JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| EP2738172A1 (fr) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | Nouveaux composés bicycliques utilisés comme modulateurs du canal crac |
| KR101823488B1 (ko) | 2013-10-14 | 2018-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| US9643967B2 (en) | 2013-12-13 | 2017-05-09 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors |
| US20170275287A1 (en) | 2014-08-22 | 2017-09-28 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| GB2534136A (en) * | 2015-01-12 | 2016-07-20 | Nokia Technologies Oy | An apparatus, a method and a computer program for video coding and decoding |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| CN109715617B (zh) | 2016-07-30 | 2022-04-19 | 百时美施贵宝公司 | 作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物 |
| ES2902504T3 (es) | 2016-09-09 | 2022-03-28 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con piridilo |
-
2017
- 2017-09-08 ES ES17768623T patent/ES2902504T3/es active Active
- 2017-09-08 JP JP2019513033A patent/JP7028861B2/ja active Active
- 2017-09-08 KR KR1020197009672A patent/KR102519535B1/ko active Active
- 2017-09-08 US US16/330,964 patent/US10660877B2/en active Active
- 2017-09-08 MA MA046188A patent/MA46188A/fr unknown
- 2017-09-08 WO PCT/US2017/050577 patent/WO2018049089A1/fr not_active Ceased
- 2017-09-08 CN CN201780068433.2A patent/CN109923108B/zh active Active
- 2017-09-08 EP EP17768623.5A patent/EP3510024B1/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102519535B1 (ko) | 2023-04-06 |
| CN109923108B (zh) | 2022-04-29 |
| EP3510024A1 (fr) | 2019-07-17 |
| CN109923108A (zh) | 2019-06-21 |
| JP2019530667A (ja) | 2019-10-24 |
| US20190262311A1 (en) | 2019-08-29 |
| JP7028861B2 (ja) | 2022-03-02 |
| KR20190045301A (ko) | 2019-05-02 |
| EP3510024B1 (fr) | 2021-11-17 |
| US10660877B2 (en) | 2020-05-26 |
| ES2902504T3 (es) | 2022-03-28 |
| WO2018049089A1 (fr) | 2018-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3720430A4 (fr) | Composés benzocarbonyle | |
| EP3802467A4 (fr) | Composés spirocycliques | |
| DK3728252T3 (da) | 4-azaindolforbindelser | |
| EP3781156A4 (fr) | Composés spirocycliques | |
| MA49701A (fr) | Composés immunomodulateurs | |
| EP3523306A4 (fr) | Composés spirocycliques | |
| EP3691623A4 (fr) | Composés de benzosulfonyle | |
| EP3558322A4 (fr) | Composés benzyl-amide phosphodiamide antiviraux | |
| EP3532069A4 (fr) | Composés aryl-amide phosphodiamide antiviraux | |
| EP3474845A4 (fr) | Composés immunomodulateurs | |
| ME03419B (fr) | Composés dihydroisoquinolinone substitués | |
| MA44233A (fr) | Nouveaux composés | |
| EP3445750A4 (fr) | Composés thérapeutiques | |
| DK3519398T3 (da) | Pyridinforbindelse | |
| EP3551176A4 (fr) | Composés hétérocycliques antidiabétiques | |
| IL280598A (en) | 2,6-diamino pyridine compounds | |
| EP3464336A4 (fr) | Composés | |
| EP3728289A4 (fr) | Composés optimisés | |
| EP3405455A4 (fr) | Composés de 2-oxindole | |
| PT3625224T (pt) | Derivados de indol n-substituídos | |
| MA49621A (fr) | Composés bifonctionnels | |
| EP3309163A4 (fr) | Dérivé de dihydropyrrolopyrazole substitué | |
| EP3310352A4 (fr) | Composés cristallins | |
| EP3717483A4 (fr) | Composés de pyrazolopyridinone | |
| EP3713941A4 (fr) | Composés de pyrazolopyridinone |